On May 26, Akeso Bio fell 3.09% in regular trading, trading at 113.5 HKD/share, with trading volume of HKD 282 million.

The decline reflects the market continuing to digest the disappointing interim analysis of its core product ivonescimab in the global pivotal Phase III HARMONi-3 study. Results disclosed by overseas partner Summit showed that the squamous cell carcinoma cohort in first-line treatment of metastatic non-small cell lung cancer failed to meet the pre-specified statistical significance threshold for progression-free survival, raising concerns over whether the strong clinical data observed in Chinese populations can be replicated globally.

Although the stock previously rebounded on catalysts including the ASCO abstract embargo lift and cadonilimab gaining clinical trial approval for a new indication, short-term valuation recovery momentum remains insufficient. The stock has now pulled back more than 25% from its prior highs.

Within the Biotechnology sector, the overall tone was weak on the same day. Among peers, BeiGene down 0.38%, 3SBio down 3.8%, Innovent Bio down 1.11%, SKB Bio up 0.34%, Remegen down 2.83%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)